Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Mode of action of aspirin as a chemopreventive agent.

Dovizio M, Bruno A, Tacconelli S, Patrignani P.

Recent Results Cancer Res. 2013;191:39-65. doi: 10.1007/978-3-642-30331-9_3. Review.

PMID:
22893199
2.

Mechanisms of the antitumoural effects of aspirin in the gastrointestinal tract.

Bruno A, Dovizio M, Tacconelli S, Patrignani P.

Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):e1-e13. doi: 10.1016/j.bpg.2012.10.001. Review.

PMID:
23199511
3.

Mechanistic and pharmacological issues of aspirin as an anticancer agent.

Dovizio M, Tacconelli S, Sostres C, Ricciotti E, Patrignani P.

Pharmaceuticals (Basel). 2012 Dec 5;5(12):1346-71. doi: 10.3390/ph5121346.

4.
5.

New Insights into the Mechanism of Action of Aspirin in the Prevention of Colorectal Neoplasia.

Di Francesco L, López Contreras LA, Sacco A, Patrignani P.

Curr Pharm Des. 2015;21(35):5116-26. Review.

PMID:
26369679
6.

The Multifaceted Clinical Readouts of Platelet Inhibition by Low-Dose Aspirin.

Patrono C.

J Am Coll Cardiol. 2015 Jul 7;66(1):74-85. doi: 10.1016/j.jacc.2015.05.012. Review.

7.

Pharmacology and cellular/molecular mechanisms of action of aspirin and non-aspirin NSAIDs in colorectal cancer.

Schrör K.

Best Pract Res Clin Gastroenterol. 2011 Aug;25(4-5):473-84. doi: 10.1016/j.bpg.2011.10.016. Review.

PMID:
22122764
8.

Aspirin, cyclooxygenase inhibition and colorectal cancer.

Sostres C, Gargallo CJ, Lanas A.

World J Gastrointest Pharmacol Ther. 2014 Feb 6;5(1):40-9. doi: 10.4292/wjgpt.v5.i1.40. Review.

9.

COX-2 is not involved in thromboxane biosynthesis by activated human platelets.

Patrignani P, Sciulli MG, Manarini S, Santini G, Cerletti C, Evangelista V.

J Physiol Pharmacol. 1999 Dec;50(4):661-7.

PMID:
10639016
10.

Cyclooxygenase-2: a novel target for cancer chemotherapy?

Dempke W, Rie C, Grothey A, Schmoll HJ.

J Cancer Res Clin Oncol. 2001 Jul;127(7):411-7. Review.

PMID:
11469677
11.

Selective inhibition of cyclooxygenase-2 enhances platelet adhesion in hamster arterioles in vivo.

Buerkle MA, Lehrer S, Sohn HY, Conzen P, Pohl U, Krötz F.

Circulation. 2004 Oct 5;110(14):2053-9. Epub 2004 Sep 27.

12.

Chemoprevention of colorectal cancer through inhibition of cyclooxygenase-2.

Dannenberg AJ, Zakim D.

Semin Oncol. 1999 Oct;26(5):499-504. Review.

PMID:
10528897
13.
14.

Cyclooxygenase as a target for chemoprevention in colorectal cancer: lost cause or a concept coming of age?

Doherty GA, Murray FE.

Expert Opin Ther Targets. 2009 Feb;13(2):209-18. doi: 10.1517/14728220802653631 . Review.

PMID:
19236238
15.

Low-dose enteric-coated aspirin: a practical approach to continuous-release low-dose aspirin and presystemic acetylation of human platelet cyclooxygenase.

Jakubowski JA, Stampfer MJ, Vaillancourt R, Faigel D, Deykin D.

J Lab Clin Med. 1986 Dec;108(6):616-21.

PMID:
3097223
16.

Inhibition of platelet prostaglandin synthetase by oral aspirin.

Burch JW, Stanford N, Majerus PW.

J Clin Invest. 1978 Feb;61(2):314-9.

17.

Ibuprofen protects platelet cyclooxygenase from irreversible inhibition by aspirin.

Rao GH, Johnson GG, Reddy KR, White JG.

Arteriosclerosis. 1983 Jul-Aug;3(4):383-8.

18.
19.
20.

Role of platelets in inflammation and cancer: novel therapeutic strategies.

Dovizio M, Alberti S, Guillem-Llobat P, Patrignani P.

Basic Clin Pharmacol Toxicol. 2014 Jan;114(1):118-27. doi: 10.1111/bcpt.12156. Epub 2013 Nov 8. Review.

Supplemental Content

Support Center